Pharvaris Director Sells $1.3 Million Worth of Shares Amid Strong Stock Performance
Johannes Gerardus Christiaan Petrus Schikan, a director at Pharvaris N.V., sold 37,600 shares for approximately $1.3 million in open-market transactions as reported on SEC Form 4 filings. The sale was part of a broader reduction strategy and executed under Rule 10b5-1 trading plans to avoid insider trading allegations. This transaction marked the largest single event among four sell transactions totaling 80,000 shares since March 2026. Schikan's direct ownership decreased by about 10.66%, leaving him with approximately $10.9 million in value based on his remaining holdings as of June 30, 2026. Pharvaris N.V., a late-stage biopharmaceutical company focused on therapies for rare diseases like hereditary angioedema, has seen its stock rise by nearly 97% over the past year. The timing aligns with strong market performance and routine liquidity activity rather than discretionary trading.
Tickers: $PHVS
Topics: insider sale NASDAQ:PHVS Pharvaris SEC Form 4